Actinic Keratosis: Current Therapies and Insights Into New Treatments


Journal

Journal of drugs in dermatology : JDD
ISSN: 1545-9616
Titre abrégé: J Drugs Dermatol
Pays: United States
ID NLM: 101160020

Informations de publication

Date de publication:
01 May 2019
Historique:
entrez: 30 5 2019
pubmed: 31 5 2019
medline: 23 7 2019
Statut: ppublish

Résumé

Actinic keratosis (AK) develops on chronically sun-exposed skin and constitutes one of the most common diseases managed by dermatologists. The incidence of AKs continues to rise among aging as well as younger sun damaged populations worldwide, underscoring the importance of effective therapy options. Various treatments are available, including light-based therapies, topical therapies, and destructive therapies. Herein, we review the current management options for AKs and discuss emerging therapeutic agents. J Drugs Dermatol. 2019;18(5 Suppl 1):s161-166.

Identifiants

pubmed: 31141862
pii: S1545961619S0161X
pii:

Substances chimiques

Dermatologic Agents 0
Imiquimod P1QW714R7M

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

s161-166.

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH